Commentary by Carl Kirkpatrick, PhD. Professor at Monash University As the number of patients diagnosed with COVID-19 exceeded the 2.5 million worldwide, the impact on the hospital systems in many cou...

Commentary by Dr. Patrick Smith With no approved treatments for COVID-19, repurposing existing drugs is an attractive option. But, getting the dose right is more complicated than it might seem.  Here...

Commentary by Dr. Craig Rayner and Dr. Karen Yeo Recently in Antiviral research, Caly et al.(1) reported the in vitro activity of ivermectin against SARS-CoV-2 in SERO cells.  The study, described th...

In response to the COVID-19 pandemic, there are over 500 global clinical trials taking place to develop life-saving treatments and vaccines for patients. In these unprecedented times, sponsors must ut...

There are unique considerations to factor in treating COVID-19 in children and pregnant women. While COVID-19 disease among children have been less severe than those in adults, the youngest appear to ...

Commentary by Mark Milad, PharmD Introduction According to the CDC, pregnant women seem to have the same risks from COVID-19 as adults who are not pregnant.1  However, pregnant women and newborns are...

Funded by the Bill & Melinda Gates Foundation, the online Center helps accelerate therapeutics for COVID-19 by integrating clinical pharmacology, innovation and collaboration PRINCETON, N.J.&#8211...

Commentary by Tom Polasek, MD, PhD, Director of Clinical Pharmacology, Certara The high morbidity and mortality rates of COVID-19 infection in the elderly highlight the importance of clinical pharmaco...

by Dr. Keith Nieforth, Senior Director PMX-SW, Certara With the continued advancement of the COVID-19 pandemic, researchers all over the globe are dedicated to finding safe and effective treatments. W...